Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer

NCT00126594 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

NIH

Sponsor class

Conditions

Clear Cell Renal Cell Carcinoma
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions

DRUG: Sorafenib Tosylate
BIOLOGICAL: Recombinant Interferon Alfa-2b
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)

Collaborators

[object Object]